Online citations, reference lists, and bibliographies.
← Back to Search

Spray Coated Pellets As Carrier System For Mucoadhesive Drug Nanocrystals.

J. Möschwitzer, R. Mueller
Published 2006 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
High pressure homogenization can be employed to produce drug nanocrystals with a number of advantages, like improved solubility behaviors, better drug targeting or even increased mucoadhesiveness. To obtain a controlled drug delivery system it is necessary to transform the resulting nanosuspension into a solid dosage form. The present study shows the feasibility to use a mucoadhesive nanosuspension of poorly soluble hydrocortisone acetate produced by high pressure homogenization as layering dispersion in a fluidized bed process, followed by the application of an enteric coating to achieve a controlled drug release. To point out the advantages of drug nanocrystals the new fomulation was compared with a formulation containing micronized drug. Both formulations were characterized with regard to their particle size and crystallinity by using laser diffractometry, photon correlation spectroscopy and X-ray diffraction. The pellet morphology was characterized by using the environmental scanning electron microscopy (ESEM). In the in vitro dissolution tests an accelerated dissolution velocity and an increased drug release could be shown for the pellets containing drug nanocrystals.
This paper references
10.1016/S0378-5173(97)00311-6
Nanosuspensions for the formulation of poorly soluble drugs: I. Preparation by a size-reduction technique
R. Mueller (1998)
10.1016/S0378-5173(00)00640-2
A new approach for targeting to Cryptosporidium parvum using mucoadhesive nanosuspensions: research and applications.
O. Kayser (2001)
10.1016/0378-5173(95)00122-Y
Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs
G. Liversidge (1995)
10.1128/AAC.45.6.1771-1779.2001
Atovaquone Nanosuspensions Show Excellent Therapeutic Effect in a New Murine Model of Reactivated Toxoplasmosis
N. Schöler (2001)
Biopharmaceutical comparison of oral multiple-unit and single-unit sustained-release dosage forms
N. Follonier (1992)
10.1023/A:1011032328064
Size-Dependent Bioadhesion of Micro- and Nanoparticulate Carriers to the Inflamed Colonic Mucosa
A. Lamprecht (2004)
10.1016/S0378-5173(01)00628-7
An oral controlled release matrix pellet formulation containing nanocrystalline ketoprofen.
G. J. Vergote (2001)
10.1201/B14855
Multiparticulate Oral Drug Delivery
I. Ghebre-Sellassie (1994)
10.1081/DDC-52073
Oral Bioadhesive Drug Delivery Systems
M. Bruschi (2005)
10.1023/A:1019854327540
Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport
I. Behrens (2004)
Pharmaceutical pelletization technology
I. Ghebre-Sellassie (1989)
10.1016/S0169-409X(00)00118-6
Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future.
R. Mueller (2001)
10.1201/b14855-8
Suspensions and dispersible dosage forms of multiparticulates
R. Bodmeier (1994)



This paper is referenced by
Water mediated solid state transformations of a polymorphic drug – effect on pharmaceutical product performance
Andres Lust (2015)
Extrusion- spheronization of pharmaceutical products : system for the delivery of active ingredients which are poorly soluble by oral route
T. T. L. Nguyen (2017)
10.1186/s40824-020-0184-8
Emerging role of nanosuspensions in drug delivery systems
Shery Jacob (2020)
10.2147/IJN.S133816
In vitro and in vivo evaluation of SN-38 nanocrystals with different particle sizes
M. Chen (2017)
DDDT_A_220876 4007..4020
Csaba Bartos (2019)
10.1016/j.ijpharm.2012.09.034
Drug nanocrystals in the commercial pharmaceutical development process.
J. Möschwitzer (2013)
10.1016/j.colsurfb.2010.10.029
Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
Y. Wang (2011)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1016/j.ijpharm.2012.12.036
D-Alpha-tocopherol acid polyethylene glycol 1000 succinate, an effective stabilizer during solidification transformation of baicalin nanosuspensions.
Pengfei Yue (2013)
10.3109/03639045.2013.831442
Enhanced recovery and dissolution of griseofulvin nanoparticles from surfactant-free nanocomposite microparticles incorporating wet-milled swellable dispersants
A. Bhakay (2014)
10.1007/978-1-4939-1399-2_13
Nanosizing: “End-to-End” Formulation Strategy for Poorly Water-Soluble Molecules
Elaine Merisko-Liversidge (2015)
DRUG NANOCRYSTALS: A NOVEL FORMULATION APPROACH FOR POORLY SOLUBLE DRUGS
Suman Katteboinaa (2009)
10.1016/j.ijpharm.2009.01.024
Diclofenac nanosuspensions: influence of preparation procedure and crystal form on drug dissolution behaviour.
F. Lai (2009)
10.1016/J.JDDST.2018.03.005
Preparation and characterization of furosemide nanosuspensions
Tugba Gulsun (2018)
10.1016/j.ijpharm.2019.04.050
Comprehensive quality by design approach for stable nanocrystalline drug products.
Rajan Jog (2019)
10.1002/jps.21563
A screening study of surface stabilization during the production of drug nanocrystals.
B. Van Eerdenbrugh (2009)
10.1186/s43094-020-00105-2
Study of homogenization on media milling time in preparation of irbesartan nanosuspension and optimization using design of experiments (DoE)
C. Borkhataria (2020)
Stabilizers used in nanocrystal based drug delivery systems
G. Shete (2014)
Nanocrystals: Current Strategies and Trends
S. Bansal (2012)
10.1007/s11095-012-0889-z
Application of Drug Nanocrystal Technologies on Oral Drug Delivery of Poorly Soluble Drugs
L. Gao (2012)
10.1016/J.AJPS.2014.08.005
Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs
V. Junyaprasert (2015)
10.1016/j.ijpharm.2016.09.046
Fast dissolution of poorly water soluble drugs from fluidized bed coated nanocomposites: Impact of carrier size.
Mohammad A Azad (2016)
10.1016/j.ejps.2008.06.009
Drying of crystalline drug nanosuspensions-the importance of surface hydrophobicity on dissolution behavior upon redispersion.
B. Van Eerdenbrugh (2008)
10.1016/j.ijpharm.2007.12.004
Size analysis of submicron particles by laser diffractometry--90% of the published measurements are false.
C. Keck (2008)
10.3390/pharmaceutics10030086
Bioavailability Enhancement of Poorly Water-Soluble Drugs via Nanocomposites: Formulation–Processing Aspects and Challenges
A. Bhakay (2018)
10.1016/j.ijpharm.2011.08.033
Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines.
J. Pardeike (2011)
10.1002/jps.24098
A brief literature and patent review of nanosuspensions to a final drug product.
W. W. Chin (2014)
Enhancing the solubility of ibuprofen using biopolymers-based nanoencapsulation
A. R. Fernandes (2016)
10.1016/B978-0-323-47720-8.00009-2
Oral pellets loaded with nanoemulsions
T. T. L. Nguyen (2017)
10.1111/j.2042-7158.2012.01520.x
Analytical methods for dissolution testing of nanosized drugs
D. Juenemann (2012)
10.1016/J.POWTEC.2014.10.024
Sub-100 micron fast dissolving nanocomposite drug powders
C. Knieke (2015)
10.1016/j.addr.2010.12.007
Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology.
E. Merisko-Liversidge (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar